Recent Advances in CAR T-Cell Therapy in Lymphoma: Insights from Experts at The John Theurer Cancer Center

Andrew Ip, MD, and Lori Leslie, MD, review clinical trial and real-world data on the efficacy and survival rates of CAR T-cell therapy in large B-cell lymphoma.

Dr Lori Leslie discusses how to assess if a patient with large B-cell lymphoma is a good candidate for CAR T-cell therapy.

Lymphoma physicians from John Theurer Cancer Center comment on the use of CAR T-cell therapy in large B-cell lymphoma and the implications of clinical trial data in this setting.

Dr Andrew Ip explains the major toxicities of CAR T-cell therapy in patients with large B-cell lymphoma and how to manage them.

Andre Goy, MD, and Andrew Ip, MD, give an overview of the approval of CAR T-cell therapy for mantle cell lymphoma treatment.

Lori Leslie, MD, explains how CAR T-cell therapy fits into follicular lymphoma treatment sequencing, highlighting data from the ZUMA-5 trial.

Drs Goy and Leslie converse on the use of CAR T-cell therapy in acute lymphoblastic lymphoma, the first approved treatment for ALL.

Dr Lori Leslie provides an overview of key clinical trial data on the use of CAR T-cell therapy in chronic lymphocytic leukemia.

Experts comment on the future of CAR T-cell therapy development and the use of dual CAR-T and CAR-T retreatment.

Drs Goy, Ip, and Leslie close out their discussion with a look at the exciting developments and future of CAR T-cell therapies in lymphoma treatment.

Key opinion leaders describe when to refer a patient with lymphoma and at what point treatments should be switched, and the evolution of T-cell engaging therapies.